A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Bristol-Myers Squibb
Study ID
NCT04088500
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specific dose on specific days
  • Ipilimumab — BIOLOGICAL
    Specific dose on specific days

Study Details

The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.

Key Dates

First listed
Sep 12, 2019
Start date
Sep 3, 2020
Status verified
Dec 2022
Primary completion
Nov 15, 2021
Completion
Nov 15, 2021

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab + Ipilimumab (combination)
    Nivolumab + Ipilimumab (combination) Q3W for 4 doses

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: From first dose up to approximately 14 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of Medicine in St. Louis WUSTLSt LouisMissouri63108-

Find similar trials in St Louis, MO

Nationwide
Kidney cancer trialsOncology trialsUrology trials
By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Washington University School of Medicine in St. Louis WUSTL· St Louis, MO

Related Studies